WallStreetZenWallStreetZen

NASDAQ: SABS
Sab Biotherapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Sab Biotherapeutics earnings were $13.3M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest SABS earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$16.9M, down 137.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SABS reported annual earnings of $13.3M, with -138.9% growth.

SABS past earnings growth

How has SABS's earnings growth performed historically?

Company
N/A
Industry
81.14%
Market
86.37%
SABS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
SABS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

SABS earnings history

Current Revenue
$0.0
Current Earnings
$13.3M
Current Profit Margin
0%

SABS Return on Equity

Current Company
15.2%
Current Industry
-9%
Current Market
29.5%
SABS's Return on Equity (15.2%)... subscribe to Premium to read more.
High Return on Equity Performance

SABS Return on Assets

Current Company
12.5%
Current Industry
-6.1%
SABS is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when SABS announces earnings.

SABS Return on Capital Employed

Current Company
8.34%
Current Industry
-0.4%
SABS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SABS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
SABS$16.60M$13.27M-51.14%$0.22
FENC-$4.53M-$6.94MN/A-$0.25
CGEN$35.87M$35.34MN/A$0.38
MDWD-$19.39M-$23.88MN/A-$2.10
PRLD-$96.25M-$99.50MN/A-$1.29
View Top Biotech Stocks

Sab Biotherapeutics Earnings Reports & History FAQ

What were Sab Biotherapeutics's earnings last quarter?

Sab Biotherapeutics (NASDAQ: SABS) reported Q4 2025 earnings per share (EPS) of -$0.51, up 58.54% year over year. Total SABS earnings for the quarter were -$16.86 million. In the same quarter last year, Sab Biotherapeutics's earnings per share (EPS) was -$1.23.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.

Is Sab Biotherapeutics profitable or losing money?

As of the last Sab Biotherapeutics earnings report, Sab Biotherapeutics is currently profitable. Sab Biotherapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $13.27 million, a 138.92% decrease year over year.

What was SABS's earnings growth in the past year?

As of Sab Biotherapeutics's earnings date in Q1 2026, Sab Biotherapeutics's earnings has grown year over year. SABS earnings in the past year totalled $13.27 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.